Get started
Author

Hongxin Piao

Observed names: H X Piao, Hong-Xin Piao, HongXin Piao, Piao, Hongxin
ORCID: 0000-0002-4396-6070
Observed ORCID: 0000-0002-4396-6070
OpenAlex ID: A5101235550
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment
2016 · Yameng Sun, Jialing Zhou, et al. · Hepatology · 177
Convallatoxin promotes apoptosis and inhibits proliferation and angiogenesis through crosstalk between JAK2/STAT3 (T705) and mTOR/STAT3 (S727) signaling pathways in colorectal cancer
2020 · Zhi Hong Zhang, Ming Yue Li, et al. · Phytomedicine · 100
On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in HBV ‐related compensated cirrhosis
2017 · Shanshan Wu, Yuanyuan Kong, et al. · Liver International · 49
Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak “stable” patients on anti-HBV therapy
2018 · Yameng Sun, Jialing Zhou, et al. · Scientific Reports · 45
PDF
Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir
2019 · Yuanyuan Kong, Yameng Sun, et al. · Journal of Viral Hepatitis · 38
Regression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events
2023 · Yameng Sun, Wei Chen, et al. · Clinical Gastroenterology and Hepatology · 34
Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study
2018 · Xiaoning Wu, Yiwen Shi, et al. · Expert Opinion on Biological Therapy · 32
Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B
2019 · Shan Shan, Hong You, et al. · Journal of Clinical and Translational Hepatology · 24
PDF
Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis
2021 · Xiaoning Wu, Jia Hong, et al. · Hepatology International · 19
Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo
2021 · Yong Jin, Hong Xiang Zuo, et al. · Frontiers in Pharmacology · 17
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
2023 · Xiaoning Wu, Xiaoqian Xu, et al. · Clinical and Molecular Hepatology · 16
PDF
A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus
2020 · Min Cong, Xiaojuan Ou, et al. · OMICS A Journal of Integrative Biology · 16
Increasing Newly Diagnosed Rate and Changing Risk Factors of HCV in Yanbian Prefecture, a High Endemic Area in China
2014 · Hong-Xin Piao, Ai-Ting Yang, et al. · PLoS ONE · 11
PDF
Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy
2021 · Xiaoning Wu, Jialing Zhou, et al. · Hepatology International · 9
Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial
2023 · Bingqiong Wang, Jialing Zhou, et al. · The American Journal of Gastroenterology · 8
Screening varices in patients with HBV‐related cirrhosis on antiviral therapy: Platelet alone or together with LSM
2020 · Bingqiong Wang, Jialing Zhou, et al. · Liver International · 8
A randomized, phase Ib trial of recombinant human serum albumin in cirrhotic patients with ascites
2025 · Xinrui Wang, Wanyu Li, et al. · Hepatology International · 7
PDF
Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis
2025 · Yameng Sun, Shuyan Chen, et al. · Hepatology · 5
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis
2023 · Yuanyuan Kong, Yameng Sun, et al. · Hepatology International · 5
Diagnostic Efficacy and Possible Underlying Mechanisms of Noninvasive Clinical Markers in Hepatocellular Carcinoma
2023 · Chao-Xu Fu, Jun Li, et al. · Journal of Clinical and Translational Hepatology · 5
PDF
On‐treatment changes of serum Wisteria floribunda agglutinin‐positive Mac‐2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add‐on therapy
2019 · Tianhui Liu, Yameng Sun, et al. · Journal of Medical Virology · 4
[Qualitative pathological assessment of liver fibrosis regression after antiviral therapy in patients with chronic hepatitis B].
2017 · Y M Sun, J L Zhou, et al. · PubMed · 4
The Optimal Cutoffs of Liver Stiffness Measurement for Staging Fibrosis in On-Treatment Patients With Chronic Hepatitis B
2025 · Xiaoning Wu, Jialing Zhou, et al. · Clinical Gastroenterology and Hepatology · 3
Treatment of Chronic Hepatitis C with Kurorinone Injection in Combination with Interferon α
2004 · Hongxin Piao · Chinese journal of integrated traditional and Western medicine · 2
Pharmacokinetics, Safety Profile, and Tolerability of MN-08 Tablets after Single and Multiple Ascending Doses in Healthy Chinese Volunteers
2026 · Enyue Yang, Mingxin Chen, et al. · Clinical Drug Investigation · 1
Works count: 31
Citation count: 640
H-index: 12
I10-index: 13
Year
Topic
Type